The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Quick Read Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivered 235% returns over the past year versus 65% for the ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

If biotech funding continues to increase this year, Danaher could benefit.

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...